March 12, 2026 — Cardiff, Wales Mariposa Therapeutics, a Cardiff-based biotech company, has secured a £750,000 seed funding round to advance pre-clinical development of MP5219, a potential first-in-class topical therapy for Epidermolysis Bullosa Simplex (EBS), a rare genetic skin disease.
The investment is led by the Development Bank of Wales, which committed up to £300,000 in equity from its Wales Technology Seed Fund. Co-investors include specialist rare disease charity DEBRA Research gGmbH and the company’s existing founders, as reported by Business News Wales and Insider Media.
Funds will support further pre-clinical studies for MP5219, securing scientific advice, early regulatory engagement, and plans for a Cardiff R&D base in 2026 following the next funding round.
Epidermolysis Bullosa Simplex (EBS)
EBS is a chronic, painful, potentially life-limiting condition causing the skin to blister and tear from minor friction or heat. No treatments currently address its underlying cause, affecting about 1 in 125,000 people in the US and Europe, and over 500,000 worldwide. EBS comprises roughly 70% of all epidermolysis bullosa cases. MP5219 activates keratin 17 expression to restore skin integrity and prevent blisters, with potential £1 billion market size and orphan drug status.
Company Background and Plans
A spin-out from Neem Biotech, Mariposa previously raised pre-seed funding led by Neem Biotech and EB Research Partnership, per the company website. Led by CEO Dr. David Howat, appointed in October 2024, and Chief Scientific Officer Dr. Lucy Sykes, the firm plans to recruit Welsh scientific staff for formulation and manufacturing.
Statements from Key Figures
“EBS is a devastating condition with no current disease-modifying treatment options. With this funding we can take MP5219 through preclinical development… We are committed to developing Mariposa as a Welsh company, and our longer-term vision is to establish a dedicated science base in Cardiff.”
— Dr. David Howat, CEO, Mariposa Therapeutics
“Our investment in Mariposa exemplifies how impact capital can accelerate… We’re excited to support the development of MP5219, which has the potential to become the first disease-modifying therapy for EBS.”
— Dr. Martin Steiner, Managing Director, DEBRA Research gGmbH
“This is an opportunity for an early-stage investment in a solution to a rare disease, which has the potential to achieve orphan drug status… The backing of DEBRA is a strong endorsement of the company’s potential.”
— Harry George, Investment Executive, Development Bank of Wales